2RAnand, Kiran Dip Gill, Abbas Ali Mahdi.Therapeutics of Alzheime r' s disease: Past, present and future [J]. Neuropharmacology, 2014, 76: 27-50.
3AP SagareR Deane, BV Zlokovic. Low-density lipoprotein receptor- related protein 1: A physiological A[3 homeostatic mechanism with multiple therapeutic opportunities [J]. Pharmacology & Therapeutics, 2012, 136:94-105.
4Deane R, Bell RD, Sagare A, et al. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease [J]. CNS NeurolDisord Drug Targets, 2009, 8(1): 16-30.
5Tanzi RE. The synapfic Abeta hypothesis of Alzheimer disease[J].Nat Neurosci, 2005, 8(8): 977-979.
6Deane R, Wu ZH,Zlokovic BV. RAGE (Yin) Versus LRP (Yang) Balance Regulates Alzheimer Arnyloid-Peptide Clearance ThroughTransport Across the Blood Brain Barrier [J]. Stroke, 2004, 35: 2628-2631.
7Grimmera T, Goldhardta O, Guo LH, et al. LRP-I polymorphism is associated with global and regional amyloid loadin Alzheimer's disease in humans in-vivo[J]. Neurolmage: Clinical, 2014, 4:411-416.
8Pflanzner T, Janko MC, Andr6 -Dohmen B, et al. LRP1 mediates bidirectional transcytosis of amyloid- 1~ across theblood-brain barrier [J]. Neurobiology of Aging, 2011, 32(2323): el-el1.
9Deane R, Sagare A, Zlokovic BV. The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clear-ance in Alzheimer's disease[J]. Curr Pharm Des, 2008, 14(16): 1601-1605.
10Cirrito JR, Deane 1L Fagan AM, et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model [J]. J Clin Invest, 2005, 115 (11): 3285-3290.
